Solid phase testing in the HLA laboratory: implications for organ allocation.
This piece was originally requested as a white paper from the Scientific and Clinical Affairs Committee of the American Society for Histocompatibility and Immunogenetics (ASHI), of which the author was then Chairman. Upon review by the ASHI Board of Directors and the Editors of their journal, it was considered too controversial for publication. It is intended to be provocative and controversial; it is not intended as a review of the literature. Though written with a decided 'American point of view', it is of importance that the issues facing US transplantation and laboratory testing efforts are shared to varying degrees by the international community, and who, unlike some of their American cousins, may be able to tolerate a spirited discussion. Sadly, we sometimes forget that dissent from dogma can be fun!
Eckels
D D
DD
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA. david.eckels@path.utah.edu
D000818:Animals; D003601:Cytotoxicity Tests, Immunologic / Q000592:standards; D006680:HLA Antigens / Q000235:genetics; D006648:Histocompatibility / Q000235:genetics*; D006650:Histocompatibility Testing / Q000592:standards*; D006801:Humans; D007753:Laboratories / Q000592:standards; D014181:Transplantation Immunology
D006680:HLA Antigens